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Abstract
Background: Periodontitis is a common disease that affects the periodontal tissue supporting the teeth. This
disease is attributed to multiple risk factors, including diabetes, cigarette smoking, alcohol, pathogenic
microorganisms, genetics and others. Human beta-defensin-1 (hBD-1) is a cationic antimicrobial peptide with
cysteine-rich ß-sheets and broad-spectrum antimicrobial activity. CD14 is a protein involved in the detection of
bacterial lipopolysaccharide (LPS) and has also been associated with periodontitis. This study investigates the single
nucleotide polymorphic (SNP) region, -1654(V38I), of the human beta-defensin-1 (hBD-1) gene as well as the -159
region of the CD14 gene in subjects with chronic periodontitis.
Methods: Blood samples from periodontally healthy subjects and periodontitis patients were obtained. DNA was
extracted from the blood and was used to perform restriction digest at the polymorphic G1654A site of DEFB1
with the enzyme HincII. The polymorphic site 159TT of CD14 was digested with the enzyme AvaII. Enzyme-linked
immunosorbent assay (ELISA) was performed on soluble samples to determine the protein expressions.
Results: The control and patient groups expressed 35% and 38% 1654 A/A genotype of DEFB1, respectively. The A
allele frequency of the control group was 40%, while the patient blood group was 54%. The mean hBD-1 protein
levels of the control and patient samples were 102.83 pg/mL and 252.09 pg/mL, respectively. The genotype
distribution of CD14 in healthy subjects was 16% for C/C, 26% for T/T and 58% for C/T. The genotype frequencies
of CD14 in periodontitis patients were 10% for C/C, 43% for T/T and 47% for C/T. The CD14 protein expression
determined by ELISA showed a mean protein level of the control samples at 76.28ng/mL and the patient blood
samples at 179.27ng/mL with a p value of 0.001.
Our study demonstrated that patients suffering from chronic periodontitis present more commonly with the
1654A/A genotype on the DEFB1 gene and the 159T/T genotype on the CD14 gene.
Conclusions: This study purely investigated the association between periodontitis and one polymorphic site on
both DEFB1 and CD14 gene, with the purpose of expanding knowledge for the future development in diagnostic
markers or therapeutic interventions to combat this disease.
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Background
Periodontitis is a chronic infectious disease[1] involving
the degradation and destruction of periodontal support-
ing tissue of the teeth[2]. This disease is highly prevalent
and can affect up to 90% of the worldwide population
[3]. The causes and risk factors include oral microorgan-
isms such as Porphyromonas gingivalis (P. gingivalis) [4],
genetic factors (Nares, 2003), acquired environmental
factors like tobacco smoking [5], uncontrolled diabetes
[6], stress [7], impaired host response [3,8], alcohol use,
HIV and AIDS, malnutrition, and osteoporosis[10]. Of
the mentioned factors, genetic polymorphisms have
attracted much attention, and a number of studies have
been conducted in different ethnic populations world-
wide to gain additional knowledge.
In recent years, a number of genetic polymorphisms and
their association with periodontal diseases have been stu-
died[11], which include interleukin (IL) -1 [12], IL-1a [13],
IL-1b [14] IL-10 (Sumer et al., 2007)[15], IL-17 [16],
matrix metalloproteinases [17] and others. Human b-
defensins (hBDs) are a group of low molecular weight (3
to 5 kDa) cationic antimicrobial peptides with cysteine-
rich ß-sheets. Defensins possess broad-spectrum antimi-
crobial activity that kill microbes by inducing physical
holes in the membrane (Li et al., 2007)[18]. They contri-
bute to host innate immunity by disrupting the membrane
integrity of a broad spectrum of microorganisms [19].
These peptides, encoded by the DEFB genes, are present
in three main gene clusters located on chromosome 8p22-
34 [20]. At least four types of defensins (hBD-1 to hBD-4)
have been characterized in humans. hBD-1 was first iso-
lated from the hemofiltrate of patients with end stage kid-
ney disease undergoing dialysis, and renal epithelia were
found as the major source [21]. Human ß defensins,
namely hBD-1 and hBD-2, have been recently identified
from plasma and various epithelial tissues [21,22].
Although a and ß defensins are encoded by different
genes, these genes share a common evolutionary origin
[23]. hBD-2 expression is induced by stimuli such as
bacteria and proinflammatory cytokine TNF-a, thereby
evoking the important functions of hBD-2 in acute inflam-
mation [23].
hBD-1 (encoded by DEFB1) and hBD-3 (encoded by
DEFB103) are constitutively expressed at low levels in
the skin [24]. hBD-1 is not normally expressed in the
circulation. hBD-2 (encoded by DEFB4) is not expressed
in normal skin but is highly expressed in inflammatory
tissues. hBD-2 is absent or at low levels in normal
epithelia. Serum hBD-2 levels in healthy individuals are
very low (less than 1 ng per ml) [25]; conversely, the
levels are highly inducible and expressed locally or sys-
temically on inflammatory stimulation [26]. The locali-
zations of hBD-2 expression include nasal [27] and oral
mucosa [28], gingival epithelia [29], human airway [30],
nasolacrimal duct [31], and ocular surface epithelium
[32], as well as intestinal epithelium [33] in response to
infection and inflammation. The constituent protein,
hBD-1, is not normally expressed in the circulation.
However, hBD-2 is inducible and expressed locally or
systemically on stimulation [26].
Genetic polymorphisms of hBD-1 and their associa-
tions with periodontitis have been investigated at SNP
sites -692 and -44, respectively [34]. The conducted stu-
dies concluded that associations do not exist for hBD-1
polymorphisms at these SNP sites and periodontitis. In
contrast, SNP site -1654 of DEFB1 has been demon-
strated to have a positive correlation with common dis-
eases such as chronic obstructive pulmonary disease
[35] and atopic dermatitis [36]. However, its association
with periodontitis has not been studied.
CD14 is a 55-kDa glycosyl phosphatidylinositol-
anchored glycoprotein expressed on the surface of white
cells [37]. As a LPS receptor it can bind to the LPS, lead-
ing to nuclear factor-B activation and cytokine expres-
sion mediated by the TLR4/MD2 complex [38]. CD14
exists in two forms: either anchored to a cell membrane
by a glycosylphosphatidylinositol tail (mCD14), or in
soluble form (sCD14). sCD14 is produced by enzymati-
cally cleaved membrane CD14, mediated mainly by phos-
pholipase C, and via secretion of CD14 [39]. Usually,
CD14 binds to LPS in the presence of lipopolysacchar-
ide-binding protein. Subsequently, a series of reactions
take place and eventually trigger intracellular signalling,
causing the production of pro-inflammatory cytokines.
Its concentration in serum has been found to increase in
several clinical pathologies, such as periodontitis [40],
rheumatoid arthritis [41], systemic lupus erythematosus
[42] and tuberculosis [43]. A SNP is found at position
-159 in the CD14 promoter, where a C to T transition
occurs [59]. Previous studies have shown an association
of the CD14-159 TT genotype with chronic periodontitis
[40], myocardial infarction [44] and pulmonary tubercu-
losis [45].
Our recent in vitro study in the reconstituted human
gingival epithelium model shows that in addition to
TLR2 and TLR4, CD14 may also be involved in the reg-
ulation of hBD-2 expression by P. gingivalis LPS [46].
Lipopolysaccharide, interleukin-1b (IL-1b), and tumor
necrosis factor-a (TNF-a) are known as highly specific
b-defensin inducers [19].
Considering the association of CD14 genetic poly-
morphisms with the severity of chronic periodontitis
[40], the present study investigated for the first time the
potential association of both hBD and CD14 polymorph-
isms and their serum levels with chronic periodontitis in
Chinese subjects.
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Methods
Selection of subjects
108 systemically healthy, non-smoking Chinese adults (39
females and 69 males, aged 18 to 60) were randomly
selected from the voluntary blood donors at Hong Kong
Red Cross between September 2004 and March 2007.
After the blood samples of these healthy volunteers were
collected, they were scheduled for oral examinations at
Keenlink Dental Clinic, Hong Kong, where they were
determined to be clinically healthy or have gingivitis,
without furcation involvement or generalized gingival
recession. All subjects who were determined to be free of
oral soft tissue abnormalities or severe dental caries were
allocated to the control group.
44 Chinese subjects (18 females and 26 males, aged 18
to 74 years) with moderate to advanced chronic periodon-
titis were recruited from West China Hospital of Stoma-
tology, Sichuan University. The diagnosis of chronic
periodontitis was made following the criteria defined by
the American Academy of Periodontology in 1999 [49].
The subject data are presented in Table 1. Both groups of
the subjects did not have more than 4 teeth missing in the
dental ridge. They did not have systemic diseases (such as
diabetes, uncontrolled hypertension), and they did have a
smoking history.
The sample size of this study was determined based
on the reports of Machin and Lemeshow. In the
report, the sample size was determined based on 0.05
level of significance for two arms to achieve 90%
power [47,48].
The study protocols were approved by the Ethics Com-
mittee, Faculty of Medicine, The University of Hong
Kong and Sichuan University, PRC. Informed consent
was obtained from all subjects.
Sampling
Peripheral blood samples were collected by direct veni-
puncture from the arm vein of each subject: 20 ml in
lithium heparin tubes and 10ml in clot blood tubes (BD
Vacutainer, NJ USA), respectively. The samples were
certrifuged for 10 min at 1,500 rotations per minute
(rpm), and serum and plasma was then collected for
enzyme-linked immunosorbent assay (ELISA) analysis.
The remaining cellular components were transferred to
a 50 ml centrifuge tube with an addition of red blood
cell lysis buffer up to 45 ml. The mixture in the tube
was inverted several times and then centrifuged for
10 min at 1,500 rpm. The supernatants were discarded,
and the remaining components were washed with 0.9%
PBS used for DNA extraction.
Extraction of DNA
Genomic DNA was extracted from each blood sample
using the QIAamp DNA Blood Mini Kit (QIAGEN,
MD, USA). The DNA concentration was estimated by
measurement of OD260. The extracted DNA was
labelled and stored at -80°C until further analysis.
Polymerase chain reaction (PCR), restriction enzyme
cleavage and gel electrophoresis
The 111 bp exon region consisting of the G1654A SNP
region of DEFB1 was amplified using the following pri-
mers: forward, 5’-CAAGCCATGAGTCTGAAGTGT-3’;
and reverse, 5’-TCAACAGTGGAGGGCAATGT-3’
according to a previous study[35]. A PCR kit (Promega
Corporation, U.S.A) was used according to the manufac-
turer’s instructions. The kit consisted of a PCR Master
Mix (50 units/ml Taq DNA Polymerase) supplied in a
proprietary reaction buffer (pH 8.5), 400 μM each of
dATP, dGTP, dCTP, dTTP, and 3 mM of MgCl2, and
nuclease free water. All procedures were carried out in a
sterile and stable environment to prevent external con-
tamination. PCR was undertaken in a thermal cycler
(MJ, U.S.A.) with a mixture containing 20 units of
nuclease-free water, 25 units of Master Mix, 0.5 units of
each primer and 3 units of extracted DNA sample. The
cycling conditions programmed were denaturation at
94°C for 5 min, followed by 30 cycles at 94°C for 30 sec,
30 sec at 56°C, extension at 72°C for 1 min, with a final
extension at 72°C for 5 min. The products from the
thermal cycling were stored at -80°C until restriction
enzyme digestion [35].
Table 1 Demographic and clinical data (Mean ± SD; % of Subjects or Sites)
Parameters Control subjects (N = 108) Periodontitis patients (N = 44)
Age (years) 42.9 ± 9.7 49.3 ± 13.6
Age range (years) 18 - 60 18 - 74
Male/female 64/36 59/41
PD (mm) 2.7 ± 1.2 6.1 ± 2.7*
Sites% with BOP 40.3 ± 9.5 78.2 ± 19.8*
Sites% with gingival recession 1 ± 1.2 38.9 ± 25.9*
Sites% with calculus 34.1 ± 13.6 63.0 ± 25.8
Clinical Attachment Loss (mm) 0.0 6.2 ± 2.9
Significant difference from the control, * p < 0.05
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The 111 bp of DEFB1 fragment generated from the PCR
procedure was digested using HincII restriction enzyme
(Fermentas Life Sciences, USA). A 10 μl aliquot of the
PCR product was mixed with 5 units of HincII, 10 μl of
nuclease free water and 1 μl of restriction enzyme buffer.
The entire mixture was incubated at 37°C for 2 hours. All
digestion reagents were kept on ice before incubation.
The electrophoresis was performed with 5 μl of diges-
tion product and 1μl of Ready-Load 1 Kb DNA Ladder
(Invitrogen, Spain) which were loaded onto a 4% agarose
gel (Invitrogen, Spain), and the gel was visualized with
ethidium bromide [35].
The analysis of -159 polymorphism of CD14 was per-
formed following a previous protocol [50]. The CD14
gene promoter was amplified by a PCR fragment of
about 500 base pairs of the following primers: forward,
5’-GTGCCAACAGATGAGGTTCAC-3’; and reverse, 5’-
GCCTCTGACAGTTTATGTAATC-3’. PCR was per-
formed with 250 ng DNA in Master Mix (Promega, WI,
USA), 12.5 µl of each pairs of primers (15 pmol). The
PCR conditions were denaturation at 94°C for 5 min,
then 30 cycles at 94°C for 30 sec, 57°C for 30 sec, exten-
sion at 72°C for 1 min, and followed by a final extension
at 72°C for 5 min. The products were stored at -80°C
until restriction enzyme digestion. The PCR products
was then digested by AvaII (Fermentas Life Sciences,
USA) at 37°C for 16 h and separated in a 2.5% agarose
gel. The gel underwent electrophoresis at 100 volts, 100
milliAmperes for 30 min. Visualization was performed
by means of a Dolphin-DOC ultraviolet illuminator
(Wealtec, South Africa).
Assay of hBD-2 and CD14 by ELISA
The supernatant of the blood samples were used for hBD-
2 and CD14 assays (ELISA kits from Phoenix Pharmaceu-
ticals Inc, USA and DIACLONE, Besançon, France,
respectively), following the manufacturer’s instructions.
100 µl of serum samples were pipetted into a 96-well
microplate for assay of hBD-2 and CD14, respectively. The
microplates were incubated at 350 rpm for 2 hours and
washed with washing buffer three times. The wells were
then dried and 200 μL of substrate tetramethylbenizidine
was added into each well for 20 min at room temperature.
The plates were then read at 450 nm wavelength using
Universal Microplate Reader (Sunrise, TECAN, Austria).
The levels of hBD-2 and CD14 were determined by com-
parison with the standard curve generated from the stan-
dards supplied by the manufacture. Each sample was
analysed in triplicates. The levels of hBD-2 and CD14
were presented as pg/ml and ng/ml, respectively.
Statistical analysis
The detection frequency and genotype distribution of
DEFB1 and CD14 polymorphisms in the patient and con-
trol groups was compared by the Chi-square test. The
relevant odds ratios between the groups were analyzed.
The difference in serum levels of hBD-2 and CD14
between the groups were evaluated with an independent
t-test. A p-value of 0.05 or less was regarded as statisti-
cally significant. Statistical analysis was performed using
SPSS 15.0 for Windows (SPSS Inc., Chicago, IL, U.S.A.).
Results
Table 1 details the clinical results of the periodontitis
patient and the healthy control groups. The periodontitis
patient group showed significantly greater means than
the healthy control group (p<0.05) for the following clini-
cal results: pocket depth (PD): 6.1 ± 2.7mm vs. 2.7 ±
1.2mm; Clinical Attachment Loss (CAL): 6.2 ± 2.9 mm
vs. 0; percentage of sites with bleeding on probing (BOP):
78.2 ± 19.8% vs. 40.3 ± 9.5% and gingival recession: 38.9
± 25.9% vs. 1 ± 1.2%. There was no significant difference
found in the age and gender ratio between the groups.
The blood count of the control subjects and periodon-
titis patients are presented in Table 2. The results were
within the normal range, although the patient group
showed a relatively higher count and percentage of lym-
phocytes and a relatively lower count and percentage of
neutrophils (p < 0.05) compared to the healthy control
group.
Table 2 Blood count (Mean ± SD) of the control subjects and periodontitis patients
Parameters Control subjects (N = 108) Periodontitis patients (N=44) Normal range Unit
White blood cell 5.03(±1.25) 3.96(±1.02) 4.00-11.00 109/L
Red blood cell 5.29(±0.11) 4.25(±0.10) 3.8-6.0 1012/L
Hemoglobin 15.9(±0.47) 12.5(±0.43) 11.5-16.5 g/dl
Platelet 256(±25.08) 241(±23.31) 150-400 109/L
Neutrophil 3.67(±1.02) *1.68(±0.71) 2.0-7.5 109/L
Lymphocyte 1.29(±0.58) *1.42(±0.26) 1.30-3.5 109/L
Monocyte 0.44(±0.17) 0.18(±0.11) 0.2-0.7 109/L
Eosinophil 0.11(±0.55) 0.06(±0.02) 0.0-0.5 109/L
Basophils 0.02(±0.02) 0.02(±0.01) 0.0-0.1 109/L
Significant difference from the control, * p < 0.05
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The DNA sequence of DEFB1 and CD14 demonstrat-
ing where SNPs occur and restriction sites are shown in
Figures 1, 2 and 3. For DEFB1, homozygous G/G alleles
were represented by a DNA band with a size of 111 bp,
and the homozygous A/A alleles were represented by
DNA bands with sizes 93 and 18 bp. Heterozygotes
Figure 1 The arrows show the HincII restriction enzyme digestion at
111 bp position of DEFB1 DNA polymorphism representing A/A, G/G
and A/G genotypes.
Figure 2 The arrows show the AvaII restriction enzyme digestion at
-159 bp promoter region of CD14 DNA polymorphism representing
T/T, C/C and T/C genotypes.
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displayed a combination of both alleles (111, 93, and 18
bp).
Homozygous C/C alleles of CD14 were represented by a
DNA band with a size of 497 bp, and the homozygous
T/T alleles were represented by DNA bands with sizes of
353 and 114 bp. Heterozygotes C/T displayed a combina-
tion of the alleles (497, 353 and 144 bp). Overall, signifi-
cant difference was found in the distribution of DEFB1
and CD14 genotypes between the groups (Table 3). For
DEFB1, the detection frequency of G allele was signifi-
cantly lower in the patient group (26%) than in the con-
trols (59%) (p < 0.001). The subjects with the G allele are
four-folded at lower risk for moderate to severe chronic
periodontitis (p < 0.001, OR = 4.111 with 95% CI 2.378 –
7.107). The genotype of G/G was significantly lower in the
patient group (20%) than the healthy controls (54%) (p <
0.001). Individuals with the G/G genotype are at approxi-
mately four times lower risk for moderate to severe peri-
odontitis than people with A/A and G/A genotypes (p <
0.001, OR = 4.511 with 95% CI 1.988 – 10.288).
For CD14, the genotype of T/T was significantly
higher in the patient group (43%) than the control
group (26%) (p < 0.05). Individuals with the T/T geno-
type are at twice a greater risk to develop moderate to
severe periodontitis than people with C/C and C/T gen-
otypes (p < 0.05, OR = 2.171, 95% CI 1.041 – 4.531).
The serum levels of hBD-2 in the patient group were
significantly higher than the levels of healthy controls (p
< 0.01) (Figure 4). Similar results were found between
the subjects with the same genotypes from the control
and patient groups. There was no significant difference
found in the serum levels of hBD-2 within the control
and patient groups who presented with different DEFB1
genotypes (Figures 5 and 6).
The serum levels of CD14 in the patient group were
significantly higher than those in the controls (p < 0.01)
(Figure 7). Similar results were found between the sub-
jects with the same genotypes from the control and
patient groups. Within the patient group, the subjects
with T/T genotype exhibited higher levels of CD14 than
subjects with C/C or C/T genotypes (p < 0.05), while no
significant difference was found in the control subjects
who presented with different CD14 genotypes (Figures 8
and 9).
Figure 3 The DNA polymorphism of CD14 at position -159 digested with restriction enzyme AvaII. The homozygous C/C alleles were
represented by a DNA band with a size of 497 bp (1 band, no cut); homozygous T/T alleles were represented by DNA bands with sizes 353 bp
and 144 bp (2 bands), whereas heterozygotes displayed a combination of C/T alleles (3 bands: 497 bp, 353 bp and 144 bp). M represented the
DNA marker.
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Discussion
hBD-1 is a cysteine-rich, cationic antimicrobial peptide
with broad-spectrum antimicrobial activity [19]. Thus,
rationally, alterations due to genetic polymorphisms at
SNP sites may be associated with asthma, HIV-1 in
pregnant women and their children, as well as oral Can-
dida carriage [51-53]. The association between DEFB1
gene polymorphism and periodontitis could not be
established in previous studies [34]. The present study,
however, demonstrated that the DEFB1 SNP at genomic
position -1654, which leads to a G to A substitution and
a valine to isoleucine substitution at polypeptide posi-
tion [35], was present more frequently in patients with
moderate to severe chronic periodontitis than the peri-
odontally healthy group. The A/A genotype is mostly
presented in the group of chronic periodontitis patients,
while the G/G genotype was exhibited in the control
group. It has been suggested that the genotypic make-
up should be constant in an individual, and any differ-
ence in polymorphic status of the genes may arise only
in circulation of the body [54].
The results of hBD-2 in serum expression support our
findings from the digests. The periodontally healthy
control group presented with a lower level (102.83 pg/
ml) of hBD-2 than the patient group (252.09 pg/ml).
The results suggest that subjects with the 1654AA geno-
type may tend to exhibit a higher serum level of hBD-2
in response to periodontal infection. Further investiga-
tions would be required to confirm this hypothesis.
Schaefer et al’s findings provide evidence for a signifi-
cant association of the rare A allele of the DEFB1 var-
iant with an increased risk for periodontal diseases [55].
This association was independent of the periodontitis-
specific covariates: smoking, diabetes and gender. The













OR (95% CI) p values OR (95% CI) p values
DEFB1
A/A 30 (69) 38 (35) 3.9474 (1.8697-
8.3339)
<0.0002* A 65 (74) 88 (41) 4.1107 (2.3775-
7.1073)
<0.0001*
G/G 9 (20) 58 (54) G 23 (26) 128 (59)
G/A 5 (11) 12 (11)
CD14
T/T 19 (43) 28 (26) 2.1714 (1.0406-
4.5311)
<0.0368* T 59 (67) 119 (55) 1.6584 (0.9868-
2.7869)
<0.05501
C/C 4 (10) 17 (16) C 29 (33) 97 (45)
C/T 21 (47) 63 (58)
DEFB1: G/G+G/A versus A/A; CD14: C/C+C/T versus T/T; OR, odds ratio; CI, confidence interval
Figure 4 Serum levels of hBD-2 (Mean ± SD) in control subjects
and periodontitis patients were measured by ELISA.
Figure 5 ELISA assay of hBD-2 (Mean ± SD) applied to measure the
serum levels in control subjects with different DEFB1 genotypes.
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robustness of the data was further supported by a sepa-
rate analysis of the two parodontopathic distinct forms:
chronic and aggressive periodontitis [55]. Their results
were comparable to our findings with a higher rate of A
genotype and A allele and a lower rate of G genotype
and G allele. The DEFB1 indicated that the G-A nucleo-
tide transition could influence the putative binding site
of its proteins [55].
The CD14-159 C > T polymorphism, a SNP at posi-
tion -159 in the promoter region of the gene encoding
this pattern recognition receptor, is associated with ele-
vated plasma/serum concentrations of soluble CD14, an
increased risk for myocardial infarction and a decreased
risk for allergies and asthma [56].
CD14 along with TLR-4 and MD-2 detects bacterial
LPS and causes the release of cytokines and antimicro-
bial peptides like hBDs. The present study extended to
investigate CD14 gene polymorphisms along with anti-
microbial peptide polymorphisms. In previous studies, it
was proven that there would be increased soluble
sCD14 levels in the saliva and serum of patients with
periodontal infection [57,58]. Currently, CD14 gene
polymorphisms are considered as potential diagnostic
markers for periodontitis. The results from this study
established the detection frequency of CD14 T/T geno-
type in periodontitis patients (43%) to be significantly
greater than periodontally healthy controls (26%). It is
interesting to note the serum levels of CD14 in the peri-
odontitis group was significantly higher than the levels
Figure 7 Serum levels of CD14 (Mean ± SD) in control subjects and
periodontitis patients measured by ELISA.
Figure 6 ELISA assay of hBD-2 (Mean ± SD) applied to measure the
serum levels in periodontitis patients with different DEFB1
genotypes.
Figure 8 ELISA assay of CD14 (Mean ± SD) applied to measure the
serum levels in control subjects with different CD14 genotypes.
Figure 9 ELISA assay of CD14 (Mean ± SD) applied to measure the
serum levels in periodontitis patients with different CD14 genotypes.
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in the controls. Similarly, periodontal patients with the
same genotypes displayed higher levels of CD14 than
their healthy subjects. Even within the periodontitis
group, subjects with the T/T genotype exhibited higher
levels of CD14 than subjects with C/C or C/T geno-
types. The current findings on an increased detection
frequency of T/T genotype in parallel with an increased
serum level of CD14 protein is consistent with other
studies on genetic polymorphisms of CD14 gene where
the T/T genotype is also shown to be more frequent in
severe periodontitis. The present study supports the
notion that a T/T genotype at the -159 position of the
CD14 gene is associated with chronic periodontitis. It is
estimated that individuals with the T/T genotype are at
twice a greater risk for moderate to severe periodontitis
than people with C/C and C/T genotypes.
Conclusions
The current study demonstrates that patients with mod-
erate to severe chronic periodontitis present more com-
monly with the -1654 A/A genotype on the DEFB1 gene
and the -159 T/T genotype on the CD14 gene, in paral-
lel with increased serum levels of hBD-2 and soluble
CD14. Within the limitations of the study, the present
findings suggest that DEFB1 and CD14 gene polymorph-
isms are significantly associated with chronic periodonti-
tis and could possibly be potential markers for
assessment of risk for periodontal disease. Further inves-
tigation is warranted to elaborate on the diagnostic
values of these potential markers in clinical practice.
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